Pathological complete response (pCR) achievement is undoubtedly the essential goal of neoadjuvant therapy for breast cancer, directly affecting survival endpoints. This retrospective study of 237 triple-negative breast cancer (TNBC) patients with a median follow-up of 36 months evaluated the role of adding platinum salts into standard neoadjuvant chemotherapy (NACT). After the initial four standard NACT cycles, early clinical response (ECR) was assessed and used to identify tumors and patients generally sensitive to NACT. BRCA1/2 mutation, smaller unifocal tumors, and Ki-67 ≥ 65% were independent predictors of ECR. The total pCR rate was 41%, the achievement of pCR was strongly associated with ECR (OR = 15.1, p < 0.001). According to multivariable analysis, the significant benefit of platinum NACT was observed in early responders ≥45 years, Ki-67 ≥ 65% and persisted lymph node involvement regardless of BRCA1/2 status. Early responders with pCR had a longer time to death (HR = 0.28, p < 0.001) and relapse (HR = 0.26, p < 0.001). The pCR was achieved in only 7% of non-responders. However, platinum salts favored non-responders' survival outcomes without statistical significance. Toxicity was significantly often observed in patients with platinum NACT (p = 0.003) but not for grade 3/4 (p = 0.155). These results based on real-world evidence point to the usability of ECR in NACT management, especially focusing on the benefit of platinum salts.

Department of Cancer Epidemiology and Genetics Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic

Department of Comprehensive Cancer Care Faculty of Medicine Masaryk University 625 00 Brno Czech Republic

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic

Department of Oncological Pathology Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic

Department of Pharmacology Faculty of Medicine Masaryk University 625 00 Brno Czech Republic

Department of Radiation Oncology Faculty of Medicine Masaryk University 625 00 Brno Czech Republic

Department of Radiation Oncology Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic

Department of Surgical Oncology Faculty of Medicine Masaryk University 625 00 Brno Czech Republic

Department of Surgical Oncology Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic

Faculty of Medicine Masaryk University 625 00 Brno Czech Republic

Research Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic

Zobrazit více v PubMed

Howlader N., Cronin K.A., Kurian A.W., Andridge R. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 2018;27:619–626. doi: 10.1158/1055-9965.EPI-17-0627. PubMed DOI

Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., Narod S.A. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007;13:4429–4434. doi: 10.1158/1078-0432.CCR-06-3045. PubMed DOI

Allison K.H., Hammond M.E.H., Dowsett M., McKernin S.E., Carey L.A., Fitzgibbons P.L., Hayes D.F., Lakhani S.R., Chavez-MacGregor M., Perlmutter J., et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch. Pathol. Lab. Med. 2020;144:545–563. doi: 10.5858/arpa.2019-0904-SA. PubMed DOI

Wolff A., Hammond E., Allison K., Harvey B., Mangu P., Bartlett J., Bilous M., Ellis I., Fitzgibbons P., Hanna W., et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch. Pathol. Lab. Med. 2018;142 doi: 10.5858/arpa.2018-0902-SA. PubMed DOI

Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., Pietenpol J.A. Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies. J. Clin. Investig. 2011;121:2750–2767. doi: 10.1172/JCI45014. PubMed DOI PMC

Burstein M.D., Tsimelzon A., Poage G.M., Covington K.R., Contreras A., Fuqua S.A.W., Savage M.I., Osborne C.K., Hilsenbeck S.G., Chang J.C., et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015;21:1688–1698. doi: 10.1158/1078-0432.CCR-14-0432. PubMed DOI PMC

Liu Y.-R., Jiang Y.-Z., Xu X.-E., Yu K.-D., Jin X., Hu X., Zuo W.-J., Hao S., Wu J., Liu G.-Y., et al. Comprehensive Transcriptome Analysis Identifies Novel Molecular Subtypes and Subtype-Specific RNAs of Triple-Negative Breast Cancer. Breast Cancer Res. BCR. 2016;18 doi: 10.1186/s13058-016-0690-8. PubMed DOI PMC

Schmid P., Adams S., Rugo H.S., Schneeweiss A., Barrios C.H., Iwata H., Diéras V., Hegg R., Im S.-A., Shaw Wright G., et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N. Engl. J. Med. 2018;379:2108–2121. doi: 10.1056/NEJMoa1809615. PubMed DOI

Cortes J., Cescon D.W., Rugo H.S., Nowecki Z., Im S.-A., Yusof M.M., Gallardo C., Lipatov O., Barrios C.H., Holgado E., et al. Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): A Randomised, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial. Lancet. 2020;396:1817–1828. doi: 10.1016/S0140-6736(20)32531-9. PubMed DOI

Robson M., Im S.-A., Senkus E., Xu B., Domchek S.M., Masuda N., Delaloge S., Li W., Tung N., Armstrong A., et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med. 2017;377:523–533. doi: 10.1056/NEJMoa1706450. PubMed DOI

Litton J.K., Rugo H.S., Ettl J., Hurvitz S.A., Gonçalves A., Lee K.-H., Fehrenbacher L., Yerushalmi R., Mina L.A., Martin M., et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N. Engl. J. Med. 2018;379:753–763. doi: 10.1056/NEJMoa1802905. PubMed DOI PMC

Schmid P., Cortes J., Pusztai L., McArthur H., Kümmel S., Bergh J., Denkert C., Park Y.H., Hui R., Harbeck N., et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N. Engl. J. Med. 2020;382:810–821. doi: 10.1056/NEJMoa1910549. PubMed DOI

Balic M., Thomssen C., Würstlein R., Gnant M., Harbeck N. St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. Breast Care. 2019;14:103–110. doi: 10.1159/000499931. PubMed DOI PMC

Cardoso F., Kyriakides S., Ohno S., Penault-Llorca F., Poortmans P., Rubio I.T., Zackrisson S., Senkus E. Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2019;30:1194–1220. doi: 10.1093/annonc/mdz173. PubMed DOI

Burstein H.J., Curigliano G., Loibl S., Dubsky P., Gnant M., Poortmans P., Colleoni M., Denkert C., Piccart-Gebhart M., Regan M., et al. Estimating the Benefits of Therapy for Early-Stage Breast Cancer: The St. Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2019;30:1541–1557. doi: 10.1093/annonc/mdz235. PubMed DOI

Pusztai L., Foldi J., Dhawan A., DiGiovanna M.P., Mamounas E.P. Changing Frameworks in Treatment Sequencing of Triple-Negative and HER2-Positive, Early-Stage Breast Cancers. Lancet Oncol. 2019;20:e390–e396. doi: 10.1016/S1470-2045(19)30158-5. PubMed DOI

Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., Bonnefoi H., Cameron D., Gianni L., Valagussa P., et al. Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. Lancet Lond. Engl. 2014;384:164–172. doi: 10.1016/S0140-6736(13)62422-8. PubMed DOI

von Minckwitz G., Untch M., Blohmer J.-U., Costa S.D., Eidtmann H., Fasching P.A., Gerber B., Eiermann W., Hilfrich J., Huober J., et al. Definition and Impact of Pathologic Complete Response on Prognosis after Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012;30:1796–1804. doi: 10.1200/JCO.2011.38.8595. PubMed DOI

Liedtke C., Mazouni C., Hess K.R., André F., Tordai A., Mejia J.A., Symmans W.F., Gonzalez-Angulo A.M., Hennessy B., Green M., et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients with Triple-Negative Breast Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008;26:1275–1281. doi: 10.1200/JCO.2007.14.4147. PubMed DOI

Mamounas E.P., Anderson S.J., Dignam J.J., Bear H.D., Julian T.B., Geyer C.E., Taghian A., Wickerham D.L., Wolmark N. Predictors of Locoregional Recurrence after Neoadjuvant Chemotherapy: Results from Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012;30:3960–3966. doi: 10.1200/JCO.2011.40.8369. PubMed DOI PMC

Wolmark N., Wang J., Mamounas E., Bryant J., Fisher B. Preoperative Chemotherapy in Patients with Operable Breast Cancer: Nine-Year Results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl. Cancer Inst. Monogr. 2001:96–102. doi: 10.1093/oxfordjournals.jncimonographs.a003469. PubMed DOI

Gass P., Lux M.P., Rauh C., Hein A., Bani M.R., Fiessler C., Hartmann A., Häberle L., Pretscher J., Erber R., et al. Prediction of Pathological Complete Response and Prognosis in Patients with Neoadjuvant Treatment for Triple-Negative Breast Cancer. BMC Cancer. 2018;18:1051. doi: 10.1186/s12885-018-4925-1. PubMed DOI PMC

Li X., Wang M., Wang M., Yu X., Guo J., Sun T., Yao L., Zhang Q., Xu Y. Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy. J. Breast Cancer. 2019;22:497–521. doi: 10.4048/jbc.2019.22.e49. PubMed DOI PMC

von Minckwitz G., Blohmer J.U., Costa S.D., Denkert C., Eidtmann H., Eiermann W., Gerber B., Hanusch C., Hilfrich J., Huober J., et al. Response-Guided Neoadjuvant Chemotherapy for Breast Cancer. J. Clin. Oncol. 2013;31:3623–3630. doi: 10.1200/JCO.2012.45.0940. PubMed DOI

Cleator S.J., Makris A., Ashley S.E., Lal R., Powles T.J. Good Clinical Response of Breast Cancers to Neoadjuvant Chemoendocrine Therapy Is Associated with Improved Overall Survival. Ann. Oncol. 2005;16:267–272. doi: 10.1093/annonc/mdi049. PubMed DOI

Hong J., Wu J., Huang O., He J., Zhu L., Chen W., Li Y., Chen X., Shen K. Early Response and Pathological Complete Remission in Breast Cancer with Different Molecular Subtypes: A Retrospective Single Center Analysis. J. Cancer. 2020;11:6916–6924. doi: 10.7150/jca.46805. PubMed DOI PMC

Byrski T., Huzarski T., Dent R., Marczyk E., Jasiowka M., Gronwald J., Jakubowicz J., Cybulski C., Wisniowski R., Godlewski D., et al. Pathologic Complete Response to Neoadjuvant Cisplatin in BRCA1-Positive Breast Cancer Patients. Breast Cancer Res. Treat. 2014;147:401–405. doi: 10.1007/s10549-014-3100-x. PubMed DOI

Telli M.L., Jensen K.C., Vinayak S., Kurian A.W., Lipson J.A., Flaherty P.J., Timms K., Abkevich V., Schackmann E.A., Wapnir I.L., et al. Phase II Study of Gemcitabine, Carboplatin, and Iniparib as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer with Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015;33:1895–1901. doi: 10.1200/JCO.2014.57.0085. PubMed DOI PMC

Von Minckwitz G., Schneeweiss A., Loibl S., Salat C., Denkert C., Rezai M., Blohmer J.U., Jackisch C., Paepke S., Gerber B., et al. Neoadjuvant Carboplatin in Patients with Triple-Negative and HER2-Positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase 2 Trial. Lancet Oncol. 2014;15:747–756. doi: 10.1016/S1470-2045(14)70160-3. PubMed DOI

Alba E., Chacon J.I., Lluch A., Anton A., Estevez L., Cirauqui B., Carrasco E., Calvo L., Segui M.A., Ribelles N., et al. A Randomized Phase II Trial of Platinum Salts in Basal-like Breast Cancer Patients in the Neoadjuvant Setting. Results from the GEICAM/2006-03, Multicenter Study. Breast Cancer Res. Treat. 2012;136:487–493. doi: 10.1007/s10549-012-2100-y. PubMed DOI

Mayer E.L., Abramson V., Jankowitz R., Falkson C., Marcom P.K., Traina T., Carey L., Rimawi M., Specht J., Miller K., et al. TBCRC 030: A Phase II Study of Preoperative Cisplatin versus Paclitaxel in Triple-Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker. Ann. Oncol. 2020;31:1518–1525. doi: 10.1016/j.annonc.2020.08.2064. PubMed DOI PMC

Couch F.J., Hart S.N., Sharma P., Toland A.E., Wang X., Miron P., Olson J.E., Godwin A.K., Pankratz V.S., Olswold C., et al. Inherited Mutations in 17 Breast Cancer Susceptibility Genes among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015;33:304–311. doi: 10.1200/JCO.2014.57.1414. PubMed DOI PMC

Alli E., Sharma V.B., Hartman A.-R., Lin P.S., McPherson L., Ford J.M. Enhanced Sensitivity to Cisplatin and Gemcitabine in Brca1-Deficient Murine Mammary Epithelial Cells. BMC Pharmacol. 2011;11:7. doi: 10.1186/1471-2210-11-7. PubMed DOI PMC

Bhattacharyya A., Ear U.S., Koller B.H., Weichselbaum R.R., Bishop D.K. The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival Following Treatment with the DNA Cross-Linking Agent Cisplatin. J. Biol. Chem. 2000;275:23899–23903. doi: 10.1074/jbc.C000276200. PubMed DOI

Kennedy R.D., Quinn J.E., Mullan P.B., Johnston P.G., Harkin D.P. The Role of BRCA1 in the Cellular Response to Chemotherapy. J. Natl. Cancer Inst. 2004;96:1659–1668. doi: 10.1093/jnci/djh312. PubMed DOI

Korde L.A., Somerfield M.R., Carey L.A., Crews J.R., Denduluri N., Hwang E.S., Khan S.A., Loibl S., Morris E.A., Perez A., et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J. Clin. Oncol. 2021 doi: 10.1200/JCO.20.03399. PubMed DOI PMC

Lokuhetty D., White V.A., Watanabe R., Cree I.A. Breast Tumours. International Agency for Research on Cancer; Lyon, France: 2019. WHO Classification of Tumours Editorial Board.

Fujii T., Kogawa T., Dong W., Sahin A.A., Moulder S., Litton J.K., Tripathy D., Iwamoto T., Hunt K.K., Pusztai L., et al. Revisiting the Definition of Estrogen Receptor Positivity in HER2-Negative Primary Breast Cancer. Ann. Oncol. 2017;28:2420–2428. doi: 10.1093/annonc/mdx397. PubMed DOI PMC

Bankhead P., Loughrey M.B., Fernández J.A., Dombrowski Y., McArt D.G., Dunne P.D., McQuaid S., Gray R.T., Murray L.J., Coleman H.G., et al. QuPath: Open Source Software for Digital Pathology Image Analysis. Sci. Rep. 2017;7:16878. doi: 10.1038/s41598-017-17204-5. PubMed DOI PMC

Er T.-K., Chang J.-G. High-Resolution Melting: Applications in Genetic Disorders. Clin. Chim. Acta Int. J. Clin. Chem. 2012;414:197–201. doi: 10.1016/j.cca.2012.09.012. PubMed DOI

Goodwin S., McPherson J.D., McCombie W.R. Coming of Age: Ten Years of next-Generation Sequencing Technologies. Nat. Rev. Genet. 2016;17:333–351. doi: 10.1038/nrg.2016.49. PubMed DOI PMC

Soukupova J., Zemankova P., Lhotova K., Janatova M., Borecka M., Stolarova L., Lhota F., Foretova L., Machackova E., Stranecky V., et al. Validation of CZECANCA (CZEch CAncer PaNel for Clinical Application) for Targeted NGS-Based Analysis of Hereditary Cancer Syndromes. PLoS ONE. 2018;13:e0195761. doi: 10.1371/journal.pone.0195761. PubMed DOI PMC

Li M.M., Datto M., Duncavage E.J., Kulkarni S., Lindeman N.I., Roy S., Tsimberidou A.M., Vnencak-Jones C.L., Wolff D.J., Younes A., et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. J. Mol. Diagn. JMD. 2017;19:4–23. doi: 10.1016/j.jmoldx.2016.10.002. PubMed DOI PMC

Daly M.B., Pilarski R., Yurgelun M.B., Berry M.P., Buys S.S., Dickson P., Domchek S.M., Elkhanany A., Friedman S., Garber J.E., et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J. Natl. Compr. Cancer Netw. JNCCN. 2020;18:380–391. doi: 10.6004/jnccn.2020.0017. PubMed DOI

U.S. Department of Health and Human Services . Common Terminology Criteria for Adverse Events (CTCAE) Version 5. U.S. Department of Health and Human Services; Washington, DC, USA: 2017.

Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., et al. New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1) Eur. J. Cancer Oxf. Engl. 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026. PubMed DOI

Cortazar P., Geyer C.E. Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer. Ann. Surg. Oncol. 2015;22:1441–1446. doi: 10.1245/s10434-015-4404-8. PubMed DOI

R Core Team European Environment Agency. [(accessed on 8 February 2021)];2020 Available online: https://www.eea.europa.eu/data-and-maps/indicators/oxygen-consuming-substances-in-rivers/r-development-core-team-2006.

Wu K., Yang Q., Liu Y., Wu A., Yang Z. Meta-Analysis on the Association between Pathologic Complete Response and Triple-Negative Breast Cancer after Neoadjuvant Chemotherapy. World J. Surg. Oncol. 2014;12:95. doi: 10.1186/1477-7819-12-95. PubMed DOI PMC

Pandy J.G.P., Balolong-Garcia J.C., Cruz-Ordinario M.V.B., Que F.V.F. Triple Negative Breast Cancer and Platinum-Based Systemic Treatment: A Meta-Analysis and Systematic Review. BMC Cancer. 2019;19:1065. doi: 10.1186/s12885-019-6253-5. PubMed DOI PMC

von Minckwitz G., Kümmel S., Vogel P., Hanusch C., Eidtmann H., Hilfrich J., Gerber B., Huober J., Costa S.D., Jackisch C., et al. Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study. J. Natl. Cancer Inst. 2008;100:552–562. doi: 10.1093/jnci/djn089. PubMed DOI

von Minckwitz G., Kümmel S., Vogel P., Hanusch C., Eidtmann H., Hilfrich J., Gerber B., Huober J., Costa S.D., Jackisch C., et al. Neoadjuvant Vinorelbine-Capecitabine versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial. J. Natl. Cancer Inst. 2008;100:542–551. doi: 10.1093/jnci/djn085. PubMed DOI

Fasching P.A., Heusinger K., Haeberle L., Niklos M., Hein A., Bayer C.M., Rauh C., Schulz-Wendtland R., Bani M.R., Schrauder M., et al. Ki67, Chemotherapy Response, and Prognosis in Breast Cancer Patients Receiving Neoadjuvant Treatment. BMC Cancer. 2011;11:486. doi: 10.1186/1471-2407-11-486. PubMed DOI PMC

Del Prete S., Caraglia M., Luce A., Montella L., Galizia G., Sperlongano P., Cennamo G., Lieto E., Capasso E., Fiorentino O., et al. Clinical and Pathological Factors Predictive of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Single Center Experience. Oncol. Lett. 2019;18:3873–3879. doi: 10.3892/ol.2019.10729. PubMed DOI PMC

Zhang F., Huang M., Zhou H., Chen K., Jin J., Wu Y., Ying L., Ding X., Su D., Zou D. A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators. Ann. Surg. Oncol. 2019;26:3912–3919. doi: 10.1245/s10434-019-07655-7. PubMed DOI

Wang Y.-J., Huang X.-Y., Mo M., Li J.-W., Jia X.-Q., Shao Z.-M., Shen Z.-Z., Wu J., Liu G.-Y. Serum Tumor Marker Levels Might Have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer. Asian Pac. J. Cancer Prev. 2015;16:4603–4608. doi: 10.7314/APJCP.2015.16.11.4603. PubMed DOI

Gamucci T., Pizzuti L., Sperduti I., Mentuccia L., Vaccaro A., Moscetti L., Marchetti P., Carbognin L., Michelotti A., Iezzi L., et al. Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study in Real-Life Setting. J. Cell. Physiol. 2018;233:2313–2323. doi: 10.1002/jcp.26103. PubMed DOI

Alba E., Lluch A., Ribelles N., Anton-Torres A., Sanchez-Rovira P., Albanell J., Calvo L., García-Asenjo J.A.L., Palacios J., Chacon J.I., et al. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. Oncologist. 2016;21:778. doi: 10.1634/theoncologist.2015-0312erratum. PubMed DOI PMC

Brown J.R., DiGiovanna M.P., Killelea B., Lannin D.R., Rimm D.L. Quantitative Assessment Ki-67 Score for Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer. Lab. Investig. J. Tech. Methods Pathol. 2014;94:98–106. doi: 10.1038/labinvest.2013.128. PubMed DOI

Loibl S., Jackisch C., Gade S., Untch M., Paepke S., Kuemmel S., Schneeweiss A., Jackisch C., Huober J., Hilfrich J., et al. Abstract S3-1: Neoadjuvant Chemotherapy in the Very Young 35 Years of Age or Younger. Cancer Res. 2012;72:S3-1. doi: 10.1158/0008-5472.SABCS12-S3-1. DOI

Ding Y., Ding K., Yang H., He X., Mo W., Ding X. Does Dose-Dense Neoadjuvant Chemotherapy Have Clinically Significant Prognostic Value in Breast Cancer?: A Meta-Analysis of 3,724 Patients. PLoS ONE. 2020;15:e0234058. doi: 10.1371/journal.pone.0234058. PubMed DOI PMC

Reinisch M., Ataseven B., Kümmel S. Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer—Review of the Literature. Breast Care Basel Switz. 2016;11:13–20. doi: 10.1159/000444543. PubMed DOI PMC

Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., Juul N., Leong C.-O., Calogrias D., Buraimoh A., et al. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010;28:1145–1153. doi: 10.1200/JCO.2009.22.4725. PubMed DOI PMC

Arun B., Bayraktar S., Liu D.D., Gutierrez Barrera A.M., Atchley D., Pusztai L., Litton J.K., Valero V., Meric-Bernstam F., Hortobagyi G.N., et al. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011;29:3739–3746. doi: 10.1200/JCO.2011.35.2682. PubMed DOI PMC

Hahnen E., Lederer B., Hauke J., Loibl S., Kröber S., Schneeweiss A., Denkert C., Fasching P.A., Blohmer J.U., Jackisch C., et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol. 2017;3:1378–1385. doi: 10.1001/jamaoncol.2017.1007. PubMed DOI PMC

Caramelo O., Silva C., Caramelo F., Frutuoso C., Almeida-Santos T. The Effect of Neoadjuvant Platinum-Based Chemotherapy in BRCA Mutated Triple Negative Breast Cancers -Systematic Review and Meta-Analysis. Hered. Cancer Clin. Pract. 2019;17:11. doi: 10.1186/s13053-019-0111-y. PubMed DOI PMC

Sharma P., Kimler B.F., O’Dea A., Nye L., Wang Y.Y., Yoder R., Staley J.M., Prochaska L., Wagner J., Amin A.L., et al. Randomized Phase II Trial of Anthracycline-Free and Anthracycline-Containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-Negative Breast Cancer (NeoSTOP) Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2021;27:975–982. doi: 10.1158/1078-0432.CCR-20-3646. PubMed DOI PMC

Wang D., Feng J., Xu B. A Meta-Analysis of Platinum-Based Neoadjuvant Chemotherapy versus Standard Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. Future Oncol. 2019;15:2779–2790. doi: 10.2217/fon-2019-0165. PubMed DOI

Sikov W.M., Berry D.A., Perou C.M., Singh B., Cirrincione C.T., Tolaney S.M., Somlo G., Port E.R., Qamar R., Sturtz K., et al. Abstract S2-05: Event-Free and Overall Survival Following Neoadjuvant Weekly Paclitaxel and Dose-Dense AC +/- Carboplatin and/or Bevacizumab in Triple-Negative Breast Cancer: Outcomes from CALGB 40603 (Alliance) Cancer Res. 2016;76:S2-05. doi: 10.1158/1538-7445.SABCS15-S2-05. DOI

Engel C., Rhiem K., Hahnen E., Loibl S., Weber K.E., Seiler S., Zachariae S., Hauke J., Wappenschmidt B., Waha A., et al. Prevalence of Pathogenic BRCA1/2 Germline Mutations among 802 Women with Unilateral Triple-Negative Breast Cancer without Family Cancer History. BMC Cancer. 2018;18 doi: 10.1186/s12885-018-4029-y. PubMed DOI PMC

Kurbel S., Dmitrović B., Marjanović K., Vrbanec D., Juretić A. Distribution of Ki-67 Values within HER2 & ER/PgR Expression Variants of Ductal Breast Cancers as a Potential Link between IHC Features and Breast Cancer Biology. BMC Cancer. 2017;17:231. doi: 10.1186/s12885-017-3212-x. PubMed DOI PMC